Laborie already held a minority interest in the manufacturer of the Optilume drug-coated balloon technology for treatment of urethral strictures and benign prostatic hyperplasia (BPH). BioWorld ...
Laborie Medical Technologies has taken another step in a steady cadence of acquisitions, picking up prostate balloon treatment maker Urotronic in a deal worth up to $600 million. The transaction ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results